Eli Lilly Price Target Raised to $1500.00/Share From $1400.00 by JP Morgan
Ratings actions from Benzinga: GMT) Eli Lilly Is Maintained at Overweight by JP MorganRatings actions from Benzinga
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
18 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI — Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
For best results when printing this announcement, please click on link below: BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design DFJ Growth & Premji Invest co-led financing with proceeds supporting advancement of Big
Novo Nordisk faces investor calls for strategy beyond Wegovy
Investors and analysts are urging Novo Nordisk CEO Mike Doustdar to outline the company's strategy beyond its blockbuster weight-loss drug Wegovy, calling for medium-term targets and acquisitions to counter looming patent cliffs and competition from Eli Lilly.
Eli Lilly Diabetes Drug Franchise Remains Strong, Analyst Praises Foundayo Trajectory
As Eli Lilly And Co (NYSE: LLY ) prepares to report third-quarter results in late October, Guggenheim analyst Seamus Fernandez maintains a Buy rating, with a raised price target from $1,273 to $1,284. While the company’s U.S. tirzepatide franchise remains strong, Fernandez says Foundayo’s trajectory is promising, with
Berenberg upgrades Eli Lilly to Buy after obesity-drug demand surge
Berenberg upgraded Eli Lilly to Buy from Hold, citing accelerating obesity-drug demand that could lead to results above the company’s ambitious 2026 outlook. Analyst Kerry Holford also raised her price target.
Eli Lilly Target Raised to $1,400 From $1,220 by Berenberg
Eli Lilly Target Raised to $1,400 From $1,220 by Berenberg
Bulls and Bears: GameStop, Marvell, Robinhood
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks ended the week lower despite a Friday rebound, as surging oil prices, rising Treasury yields and growing expectations for a Federal Reserve rate hike pressured equities. The S&P 500 fell
HSBC raises Eli Lilly price target to $940 from $850
Benzinga reports HSBC raised its Eli Lilly price target to $940.00 per share from $850.00.
Nasdaq 100 falls as hot PCE inflation lifts rate-hike bets
U.S. stocks drifted lower midday Wednesday after July PCE inflation met monthly forecasts but ran hotter than expected annually, while second-quarter GDP growth was confirmed at an annualized 1.5%.
Eli Lilly Target Raised
Leerink raises target price
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Inc. (NYSE: COR ) on Wednesday reported third-quarter adjusted earnings of $4.48 per share, beating the consensus of $4.35. The pharmaceutical solutions organization reported sales of $84.754 billion, up 5.1% year-over-year, beating the consensus of $84.315 billion, driven by steady demand across its health car
Jim Cramer: Arista Is ‘Terrific,’ Also Likes This Consumer Cyclical Stock
On CNBC’s “ Mad Money Lightning Round,” Jim Cramer said he likes Ross Stores, Inc. (NASDAQ: ROST ). On the earnings front, Ross Stores, on May 21, reported better-than-expected first-quarter financial results and raised its FY26 GAAP EPS guidance above estimates. Ross Stores reported quarterly earnings of $2.02 per sha
Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
() -- Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday. The investment firm revised its price targets for several biopharma stocks it covers ah
Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says
() -- Eli Lilly (LLY) is expected to deliver Q2 revenue slightly above consensus on stronger-than-anticipated sales of Mounjaro and Zepbound, RBC Capital Markets said Wednesday in a report. RBC forecasts Q2 revenue of about $20.7 billion, ahead of the $20.5 billion consensus estimate, driven by 5% to 6% beats for the d
Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says
() -- Eli Lilly (LLY) is poised to outpace second-quarter sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC Capital Markets said in a note Wednesday. The brokerage expects second-quarter revenue of $20.74 billion, ahead of
Eli Lilly price target raised to $1,400 from $1,300 at JPMorgan
JPMorgan raised the firm's price target on Eli Lilly to $1,400 from $1,300 and keeps an Overweight rating on the shares. The firm sees potential upside for Mounjaro from growth in the U.S. obesity market and internationally, the analyst tells investors in a Q2 earnings preview.
Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
HSBC downgraded Pfizer Inc. (NYSE: PFE ) on Monday, citing that the company’s near-term re-rating prospects have weakened despite its attractive dividend yield and long-term oncology ambitions. Analysts Rajesh Kumar and Dylan Whitfield downgraded to Hold from Buy and lowered their target forecast to $28 from $32, citin